Tycel Phillips, MD, on Glofitamab Research, Progress in Mantle Cell Lymphoma
By Tycel Phillips, MD, Leah Sherwood - Last Updated: January 25, 2023Tycel Phillips, MD, of the City of Hope, discusses a study of glofitamab, a bispecific antibody, in patients with relapsed/refractory mantle cell lymphoma (MCL). Dr. Phillips also shares his thoughts on the next steps for glofitamab research in patients with MCL, the future of bispecific antibody treatments, and more.
Related Posts
Michael Dickinson, MBBS, DMedSc, discusses trials in progress that are evaluating glofitamab with other agents for DLBCL.
Michael Dickinson, MBBS, DMedSc, discusses a phase II trial of glofitamab, a bispecific antibody, in patients with DLBCL.
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
Michael Dickinson, MBBS, DMedSc, discusses updates on glofitamab that were presented during the 2022 ASH meeting.
Advertisement
Editorial Board
Sagar Lonial, MD, FACPSagar Lonial, MD, FACP, of the Winship Cancer Institute, is Editor-in-Chief of Blood Cancers Today.
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Advertisement
670 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.